contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


nordic-nanovector-notice-of-annual-general-meeting-on-28-june-2023-1

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Thor Medical is a manufacturer and supplier of alpha particle emitters for cancer treatment. Radionuclide therapy (RNT) or radioligand therapy (RLT) using alpha particle emitters is a promising technology for cancer treatment. The main focus of the company is to refine the production technology, secure the customer base and necessary regulatory approvals for industrialization. Thor Medical is headquartered in Oslo.

Thor Medical

Notice is given that the Annual General Meeting of Nordic Nanovector ASA will be held on 28 June 2023, at 14:00 hours CEST at Advokatfirmaet CLP, Sommerrogata 13 -15, 0255 Oslo. The full notice...

<pre>Notice is given that the Annual General Meeting of Nordic Nanovector ASA will be held on 28 June 2023, at 14:00 hours CEST at Advokatfirmaet CLP, Sommerrogata 13 -15, 0255 Oslo. The full notice is attached. The notice and the documents to which it refers are also available on &nbsp;(http://www.nordicnanovector.com)www.nordicnanovector.com. Shareholders wishing to attend the Annual General Meeting, in person or by proxy, must complete and return the attendance form or power of attorney form attached to the notice to Nordea Bank Abp, Issuer Service, Postboks 1166 Sentrum, N-0107 Oslo, or by e-mail to nis@nordea.com no later than 26 June 2023, 16:00 CEST. Attendance or proxies may also be registered electronically through Euronext Securities Oslo (formerly VPS) Investor Services. For further information, please contact: IR enquiries Ludvik Sandnes, Interim CEO &amp; CFO Cell: +47907 43 017 Email:ir@nordicnanovector.com About Nordic Nanovector: Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. Further information can be found atwww.nordicnanovector.com&nbsp;(https://nam10.safelinks.protection.outlook.com/?url= h ttp%3A%2F%2Fwww.nordicnanovector.com%2F&amp;data=04%7C01%7CMark.Swallow%40medistrava . com%7Cbd8fdb7f05284d3963a108d9d20ae447%7C5c24475f929349d0b4e1ba6d190e92f9%7C0%7C 0 %7C637771766496096573%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMz I iLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000&amp;sdata=xp8WBxqCMdEa4qM%2FjJAyw9bnfalGpQqsw X zSzRJqqWo%3D&amp;reserved=0). </pre>